Free Trial
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Nautilus Biotechnology logo
$2.32 -0.02 (-0.85%)
(As of 09:57 AM ET)

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Key Stats

Today's Range
$2.30
$2.39
50-Day Range
$2.24
$3.08
52-Week Range
$2.19
$3.45
Volume
15,649 shs
Average Volume
78,461 shs
Market Capitalization
$291.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Moderate Buy

Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
35th Percentile Overall Score

NAUT MarketRank™: 

Nautilus Biotechnology scored higher than 35% of companies evaluated by MarketBeat, and ranked 768th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nautilus Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Nautilus Biotechnology has received no research coverage in the past 90 days.

  • Read more about Nautilus Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nautilus Biotechnology is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nautilus Biotechnology is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nautilus Biotechnology has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nautilus Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    1.61% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    Nautilus Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Nautilus Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.61% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.
  • Change versus previous month

    • Insider Buying vs. Insider Selling

      In the past three months, Nautilus Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $234,729.00 in company stock.

    • Percentage Held by Insiders

      40.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Nautilus Biotechnology's insider trading history.
    Receive NAUT Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

    NAUT Stock News Headlines

    My #1 Pre IPO Trade for 2025 – NAME and TICKER
    One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...
    Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
    See More Headlines

    NAUT Stock Analysis - Frequently Asked Questions

    Nautilus Biotechnology's stock was trading at $2.99 on January 1st, 2024. Since then, NAUT shares have decreased by 21.7% and is now trading at $2.34.
    View the best growth stocks for 2024 here
    .

    Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its earnings results on Tuesday, October, 29th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04.

    Top institutional shareholders of Nautilus Biotechnology include State Street Corp (0.74%), Wexford Capital LP (0.18%), Clearline Capital LP (0.11%) and Barclays PLC (0.08%). Insiders that own company stock include Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld, Perceptive Advisors Llc, Mary E Godwin and Matthew L Posard.
    View institutional ownership trends
    .

    Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
    Compare Top Brokerages Here.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

    Company Calendar

    Last Earnings
    10/29/2024
    Today
    11/21/2024
    Fiscal Year End
    12/31/2024
    Next Earnings (Estimated)
    2/26/2025

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Analytical instruments
    Sub-Industry
    Measuring And Control Equipment
    Current Symbol
    NASDAQ:NAUT
    Fax
    N/A
    Employees
    130
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $4.50
    High Stock Price Target
    $6.00
    Low Stock Price Target
    $3.00
    Potential Upside/Downside
    +92.3%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    Net Income
    $-63,670,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Book Value
    $2.12 per share

    Miscellaneous

    Free Float
    74,711,000
    Market Cap
    $293.82 million
    Optionable
    Optionable
    Beta
    1.23
    The Best High-Yield Dividend Stocks for 2024 Cover

    Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

    Get This Free Report

    This page (NASDAQ:NAUT) was last updated on 11/21/2024 by MarketBeat.com Staff
    From Our Partners